Crewe Advisors’s Travere Therapeutics TVTX Stock Holding History

Crewe Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-196	Closed	-$4.41K	–	1008
2023 Q1	$4.41K	Hold	196	–	–	﹤0.01%	647
2022 Q4	$4.12K	Hold	196	–	–	﹤0.01%	708
2022 Q3	$5K	Hold	196	–	–	﹤0.01%	863
2022 Q2	$5K	Buy	+196	New	+$4.93K	﹤0.01%	778

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Crewe Advisors's TVTX Position: Q2 2023 in Review

Crewe Advisors sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 196 shares — an estimated $4.41K sold.

Crewe Advisors first reported a position in TVTX in Q2 2022 and held it in 4 quarters. The position peaked at $5K in Q3 2022. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Crewe Advisors reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
Crewe Advisors sold 196 Travere Therapeutics shares in Q2 2023, an estimated $4.41K.
Crewe Advisors first reported a position in Travere Therapeutics in Q2 2022 and held it in 4 quarters.
Crewe Advisors's Travere Therapeutics position peaked at $5K in Q3 2022.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Crewe Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.